Vischer with FimmCyte on partnership with Gedeon Richter
Vischer advised FimmCyte, a Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, in connection with its research collaboration and option-to-license agreement with Gedeon Richter, a pharmaceutical company specialised in women’s health, with headquarters in Hungary.
Within the new collaboration, FimmCyte will conduct joint research and development activities with Gedeon Richter, which will have global exclusive rights should they decide to exercise their option prior to initiation of the first-in-human clinical study.
The Vischer team
Managing associate Luzius Zumstein (pictured left) and partner Christian Wyss (pictured right), both from Vischer’s life science practice, led the firm’s team on the matter.
